Date | Price Target | Rating | Analyst |
---|---|---|---|
8/8/2024 | Hold → Sell | Deutsche Bank | |
7/29/2024 | $15.00 → $6.00 | Overweight → Equal-Weight | Morgan Stanley |
7/11/2024 | Buy → Hold | Deutsche Bank | |
4/12/2024 | Hold → Buy | Deutsche Bank | |
1/18/2024 | Sector Perform → Outperform | RBC Capital Mkts | |
6/23/2023 | $12.00 → $16.00 | Equal-Weight → Overweight | Morgan Stanley |
6/16/2023 | $13.00 | Buy → Neutral | BofA Securities |
6/8/2023 | Neutral → Buy | Citigroup |
Softness in market for Shared R&D Services, with H1 2024 revenues down 7% year-on-year. Continued growth of sales order book in Discovery - higher share of integrated long-term deals will improve revenue contribution beyond 2024Strong progress of Just - Evotec Biologics with H1 2024 revenues increase of 50% year-on-year; capacity ramp-up for J.POD in Toulouse has been acceleratedChallenging market environment and high fixed cost base led to weaker profitability. Priority reset towards profitable growth gaining momentumDr Christian Wojczewski, CEO as of 1 July, is announcing an accelerated transformation programme for the company, building on the core innovation strengths of Evotec HAMBURG, G
HAMBURG, GERMANY / ACCESSWIRE / August 7, 2024 / Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) will announce its financial results for the first half-year of 2024 on Wednesday, 14 August 2024.The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in English.Webcast detailsDate: Wednesday, 14 August 2024Time: 2.00 pm CEST (01.00 pm BST, 08.00 am EDT)To join the audio webcast and to access the presentation slides, please register via this link.The on-demand version of the webcast will be available on our website: www.evotec.com/en/investor-relations/financial-public
CHALLENGING Q1 WITH SOFTNESS MAINLY IN TRANSACTIONAL/DEVELOPMENT SHARED R&D BUSINESS AGAINST A STRONG COMPARABLE QUARTERSTRONG START WITH JUST - EVOTEC BIOLOGICS IN Q1 2024POSITIVE MOMENTUM IN SHARED R&D DISCOVERY CLOSED SALES POINT TO RECOVERY OF REVENUES TOWARDS END OF THE YEARRESET FOR PROFITABLE GROWTH INITIATED, NEW REPORTING SEGMENTS INTRODUCED: SHARED R&D AND JUST - EVOTEC BIOLOGICSHAMBURG, GERMANY / ACCESSWIRE / May 22, 2024 / Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) today announced financial results and corporate updates for the first quarter 2024.HIGHLIGHTSEVOTEC'S TRANSACTIONAL BUSINESS IMPACTED BY HEADWINDS; STRONG GROWTH IN JUST - EVOTEC BIO
SC 13G/A - Evotec SE (0001412558) (Subject)
SC 13G/A - Evotec SE (0001412558) (Subject)
SC 13G - Evotec SE (0001412558) (Subject)
Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies HAMBURG, GERMANY / ACCESSWIRE / September 26, 2024 / Evotec SE ((Frankfurt Stock Exchange:EVT, SDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) announced today that Evotec has entered a technology development partnership with Novo Nordisk in cell therapy.Both Evotec and Novo Nordisk have significant expertise and a strategic focus to support stem cell-based therapies. In order to provide next-generation off-the-shelf cell therapy products for clinical development and possible commercialisation thereafter, the companies will collaborate on developm
J.POD® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the regionJust - Evotec Biologics' J.POD® technology offers a paradigm shift in biomanufacturing with cost-effective and flexible clinical and commercial supply solutionsHAMBURG, GERMANY and TOULOUSE, FRANCE / ACCESSWIRE / September 20, 2024 / Just - Evotec Biologics, the biologics segment of Evotec SE (Frankfurt Stock Exchange:EVT)((MDAX/TecDAX, OTC:EVOTF)(NASDAQ:EVO), today celebrated the Grand Opening of its J.POD® biologics development and manufacturing facility located on Evotec's Campus Curie in Toulouse, France. The J.POD® facility in Toulouse, the second of its kind and the first
Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) and X-Chem, leader in DNA-encoded library (DEL) technology, today announced a collaboration agreement focused on accelerating early-stage drug discovery. X-Chem's DEL technology streamlines hit finding by simultaneously screening up to billions of DNA-tagged compounds, identifying potential start points with high efficiency and precision. In partnership with Evotec's screening platforms and capabilities, X-Chem is providing access to its DEL technology, including DELflex, a traditional experimental DEL solution, and HITMiner, a machine learning solution, leveraging high quality experimental DEL data to delive
20-F - Evotec SE (0001412558) (Filer)
6-K - Evotec SE (0001412558) (Filer)
6-K - Evotec SE (0001412558) (Filer)
U.S. stock futures were lower this morning, with the Dow futures falling over 50 points on Thursday. Shares of Delta Air Lines, Inc. (NYSE:DAL) fell sharply in today's pre-market trading after the company posted downbeat second-quarter earnings and issued lower-than-expected third-quarter earnings outlook. Delta Air Lines reported quarterly earnings of $2.36 per share which missed the analyst consensus estimate of $2.37 per share. The company reported quarterly sales of $16.658 billion which beat the analyst consensus estimate of $15.452 billion, according to data from Benzinga Pro. Delta Air Lines shares fell 9% to $42.65 in the pre-market trading session. Here are some big stoc
Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases The research will be carried out at Evotec's sites in France, including Campus Curie in Toulouse, a state-of-the-art research site with capabilities spanning high throughput screening, in vitro and in vivo biology, proteomics and metabolomics. Evotec will receive research support funding from Pfizer and be eligible for potential milestones and royalties related to success of the programs.
German drug developer Evotec SE (NASDAQ:EVO) is reportedly consulting defense advisers following a significant drop in share price, raising concerns about the company’s vulnerability to a takeover. Multiple buyout firms are reportedly evaluating Hamburg-based Evotec as a potential acquisition target, initiating early discussions with advisers to assess the company’s drug pipeline and strategic value. Evotec’s shares surged. The spike follows a year-to-date decline of over 60%, with the stock recently hitting its lowest since March 2017. The drop came after Intron Health analysts downgraded the stock from “buy” to “sell.” Bloomberg noted, citing sources, that despite the market activ
Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies HAMBURG, GERMANY / ACCESSWIRE / September 26, 2024 / Evotec SE ((Frankfurt Stock Exchange:EVT, SDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) announced today that Evotec has entered a technology development partnership with Novo Nordisk in cell therapy.Both Evotec and Novo Nordisk have significant expertise and a strategic focus to support stem cell-based therapies. In order to provide next-generation off-the-shelf cell therapy products for clinical development and possible commercialisation thereafter, the companies will collaborate on developm
Most agenda items adopted with great majorityAnnual General Meeting 2024 elects Dr Duncan McHale and Wesley Wheeler to the Supervisory Board, replacing Dr Elaine Sullivan and Dr Mario PolywkaHAMBURG, GERMANY / ACCESSWIRE / June 10, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((MDAX/TecDAX, OTC:EVOTF)(NASDAQ:EVO) today announced that its shareholders approved most of the proposals the Company's Management put to vote at the Company's Annual General Meeting 2024 with great majority.Under the topic "Together for Medicines that Matter - Weg zum Neustart", the Chairperson of the Supervisory Board of Evotec SE, Prof. Dr Iris Löw-Friedrich, Chief Business Officer Dr Matthias Evers and Chief Fina
HAMBURG, GERMANY / ACCESSWIRE / April 23, 2024 / The Supervisory Board of Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) has appointed Dr Christian Wojczewski as the Company's new Chief Executive Officer ("CEO"), effective 01 July 2024. The election was unanimous and is the result of an extensive selection process that began in January.Dr Mario Polywka, who has led Evotec as Interim CEO since 03 January 2024, will retire from his position at the end of June and will also not seek re-election for his dormant Supervisory Board mandate, which expires with the 2024 Annual General Meeting.Dr Christian Wojczewski holds a degree in chemistry and has over 20 years of
Deutsche Bank downgraded Evotec SE from Hold to Sell
Morgan Stanley downgraded Evotec SE from Overweight to Equal-Weight and set a new price target of $6.00 from $15.00 previously
Deutsche Bank downgraded Evotec SE from Buy to Hold